EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort

Andrea-Hermina Györfi iD, Tim Filla, Amin Polzin iD, Koray Tascilar iD, Maya Buch iD, Monique Tröbs iD, Alexandru-Emil Matei iD, Paolo Airo iD, Alexandra Balbir-Gurman iD, Frederic Kuwert, Carina Mihai iD, Anna Kabala und 23 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.036730 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Andrea-Hermina Györfi und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University Düsseldorf Germany. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Heart Failure. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderma Trials and Research) cohort.

Methods

SSc‐pHI was defined according to the World Scleroderma Foundation/Heart Failure Association definition. Data from 5741 patients with SSc in the EUSTAR cohort were analyzed. Additional cardiovascular data were collected from a subcohort of 838 patients with SSc. Lasso regression was used for risk factor analyses. Kaplan–Meier estimator was used for survival analyses. Progression of SSc‐pHI was evaluated by a study definition developed by rheumatology and cardiology experts.

Results

Risk factors for the presence of SSc‐pHI comprised skeletal muscle atrophy (odds ratio [OR], 2.00 [95% CI, 1.00–2.68]), age (OR, 1.91 [95% CI, 1.73–2.03]), male sex (OR, 1.77 [95% CI, 1.42–2.05]), swollen joints (OR, 1.70 [95% CI, 1.47–1.98]), skeletal muscle weakness (OR, 1.38 [95% CI, 1.00–1.85]), and tendon friction rubs (OR, 1.46 [95% CI, 1.00–1.77]) (n=3276). Telangiectasia (OR, 2.10 [95% CI, 1.38–2.72]), intestinal symptoms (OR, 1.70 [95% CI, 1.04–2.42]), age (OR, 1.47 [95% CI, 1.21–1.62]), and antitopoisomerase I antibodies (OR, 1.37 [95% CI, 1.00–1.77]) were associated with an increased risk for new onset of SSc‐pHI (n=1000). Survival rate was significantly lower in patients with SSc‐pHI than in those without ( P value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicHeart FailureHumansMaleFemaleMiddle AgedEuropeDisease ProgressionAgedRisk FactorsChronic DiseaseRisk AssessmentAdult

Stichwörter der Autor:innen

EUSTAR cohortmortalityrisk factorssystemic sclerosissystemic sclerosis primary heart involvement

Autor:innen und Institutionen

  • Department of Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University Düsseldorf Germany.
  • Hiller Research Center University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University Düsseldorf Germany.
  • Department of Cardiology, Pneumology, and Angiology University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University Düsseldorf Germany.
  • Department of Internal Medicine 3, Rheumatology and Clinical Immunology Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen Erlangen Germany.
  • Deutsches Zentrum Immuntherapie (DZI) Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen Erlangen Germany.
  • Department of Rheumatology University of Manchester Manchester UK.

ORCID-Profile: Andrea-Hermina Györfi, Amin Polzin, Koray Tascilar, Maya Buch, Monique Tröbs, Alexandru-Emil Matei, Paolo Airo, Alexandra Balbir-Gurman, Carina Mihai, Hanna Graßhoff, Yohei Isomura, Julia Spierings, Anders Heiervang Tennoe, Anna-Maria Hoffmann-Vold, Christina Bergmann, Georg Schett, Jacob M van Laar, Lesley Ann Saketkoo, Masataka Kuwana, Elise Siegert, Gabriela Riemekasten, Oliver Distler, Tessa du Four, Vanessa Smith, Marie-Elise Truchetet, Jörg H W Distler

Zitieren

APA

Györfi, A. H., Filla, T., Polzin, A., Tascilar, K., Buch, M., Tröbs, M., Matei, A. E., Airo, P., Balbir-Gurman, A., Kuwert, F., Mihai, C., Kabala, A., Graßhoff, H., Callaghan, J., Isomura, Y., Mansour, J., Spierings, J., Tennoe, A. H., Selvi, E., …, & EUSTAR collaborators (2025). Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036730

Vancouver

Györfi AH, Filla T, Polzin A, Tascilar K, Buch M, Tröbs M, et al. Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.036730

BibTeX
@article{Gyrfi2025,
  author = {Györfi, Andrea-Hermina and Filla, Tim and Polzin, Amin and Tascilar, Koray and Buch, Maya and Tröbs, Monique and Matei, Alexandru-Emil and Airo, Paolo and Balbir-Gurman, Alexandra and Kuwert, Frederic and Mihai, Carina and Kabala, Anna and Graßhoff, Hanna and Callaghan, Julia and Isomura, Yohei and Mansour, Jennifer and Spierings, Julia and Tennoe, Anders Heiervang and Selvi, Enrico and Riccieri, Valeria and Hoffmann-Vold, Anna-Maria and Bergmann, Christina and Schett, Georg and Hunzelmann, Nicolas and van Laar, Jacob M and Saketkoo, Lesley Ann and Kuwana, Masataka and Siegert, Elise and Riemekasten, Gabriela and Distler, Oliver and du Four, Tessa and Smith, Vanessa and Truchetet, Marie-Elise and Distler, Jörg H W and EUSTAR collaborators, EUSTAR collaborators},
  title = {Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.036730}
}
Kostenlos starten →